Patents by Inventor Sabine Lang

Sabine Lang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240059584
    Abstract: The present invention relates to a filtration device comprising an inlet funnel with a cartridge seat, a filter cartridge placeable in the cartridge seat, and a sensing apparatus comprising sensing means for measuring at least one water characteristic. The sensing apparatus comprises an electrical circuit with a control gap and the filter cartridge comprises a bridging element, wherein the bridging element is arranged such that it electrically closes the control gap when the filter cartridge is located in the cartridge seat.
    Type: Application
    Filed: December 16, 2021
    Publication date: February 22, 2024
    Inventors: Uwe LANG, Sabine LANG-DRESS
  • Publication number: 20230357397
    Abstract: The present invention relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and/or agents blocking PD-L1/PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: February 9, 2023
    Publication date: November 9, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Christina CLAUS, Claudia FERRARA KOLLER, Christian KLEIN, Sabine LANG, Viktor LEVITSKI, Pablo UMAÑA
  • Publication number: 20210138065
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD79b antibody-drug conjugate.
    Type: Application
    Filed: December 18, 2020
    Publication date: May 13, 2021
    Applicants: HOFFMANN-LA ROCHE INC., GENENTECH, INC.
    Inventors: Christian KLEIN, Sabine LANG, Pablo UMANA, Andrew G. POLSON
  • Publication number: 20200392237
    Abstract: The present invention relates to combination therapies employing tumor targeted bispecific OX40 antibodies, in particular anti-FAP/anti-OX40 antibodies in combination with T-cell activating anti-CD3 bispecific antibodies specific for a tumor-associated antigen, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: April 28, 2020
    Publication date: December 17, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Sandra GRAU-RICHARDS, Christian KLEIN, Johannes SAM, Pablo UMANA, Sabine LANG, Maria AMANN, Mudita PINCHA
  • Publication number: 20200325225
    Abstract: The present invention relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and/or agents blocking PD-L1/PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: March 20, 2020
    Publication date: October 15, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Christina CLAUS, Claudia FERRARA KOLLER, Christian KLEIN, Sabine LANG, Viktor LEVITSKI, Pablo UMAÑA
  • Publication number: 20180344848
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD79b antibody-drug conjugate.
    Type: Application
    Filed: August 10, 2018
    Publication date: December 6, 2018
    Applicants: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: Christian Klein, Sabine Lang, Pablo Umana, Andrew Polson
  • Publication number: 20180133315
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD79b antibody-drug conjugate.
    Type: Application
    Filed: November 9, 2017
    Publication date: May 17, 2018
    Applicants: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: Christian Klein, Sabine Lang, Pablo Umana, Andrew Polson
  • Publication number: 20170306040
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD22 antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD22 antibody-drug conjugate.
    Type: Application
    Filed: March 7, 2017
    Publication date: October 26, 2017
    Applicants: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: Christian Klein, Sabine Lang, Pablo Umana, Andrew Polson
  • Publication number: 20150010540
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD22 antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD22 antibody-drug conjugate.
    Type: Application
    Filed: April 30, 2014
    Publication date: January 8, 2015
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.
    Inventors: Christian Klein, Sabine Lang, Pablo Umana, Andrew Polson
  • Publication number: 20140356352
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD79b antibody-drug conjugate.
    Type: Application
    Filed: April 30, 2014
    Publication date: December 4, 2014
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.
    Inventors: Christian Klein, Sabine Lang, Pablo Umana, Andrew Polson
  • Patent number: 6073504
    Abstract: A drive unit provided with an end position recognition device includes a radially projecting cam (27) connected to a driveshaft (20) of the drive unit, for reducing the stroke travel of the unit. The radially projecting cam engages, from tooth to tooth, into the inner toothing of a ratchet wheel (110), rotatable about an axis of rotation (111) that is offset and parallel to an axis of the driveshaft (20). The end position recognition device can be retrofitted and is preferably capable of operating even in the case of emergency manual actuation. The cam (27) has a sufficient axial stroke lift such that, in the case of emergency manual actuation, it nonetheless meshes with the ratchet wheel (110) even when the driveshaft (20) is displaced axially.
    Type: Grant
    Filed: February 10, 1998
    Date of Patent: June 13, 2000
    Assignee: Siemens Aktiengesellschaft
    Inventors: Ronald Gleixner, Peter Landwehr, Sabine Lang